Keywords
metabolik sindrom
oksidlovchi stress
sitoxrom
How to Cite
Abstract
Mazkur tizimli-analitik sharh jigarning detoksifikatsiya (zararsizlantirish) funksiyasi va metabolik sindrom o‘rtasidagi patofiziologik bog‘liqliklarni hamda ushbu munosabatning zamonaviy terapevtik strategiyalardagi ahamiyatini baholashga bag‘ishlangan. Tadqiqotning asosiy maqsadi jigar biotransformatsiyasining uch fazasi (I-faza — sitoxrom P450 fermentlari, II-faza — konjugatsiya reaksiyalari, III-faza — transport tizimlari) hamda Nrf2–Keap1–ARE antioksidant signal yo‘lining metabolik sindrom sharoitida o‘zgarishini, insulin rezistentligi va oksidlovchi stress bilan o‘zaro ta’sirini tizimli tahlil qilishdan iborat bo‘ldi. Sharh PRISMA tavsiyalariga muvofiq Scopus, Web of Science, PubMed/MEDLINE va ScienceDirect ma’lumotlar bazalarida chop etilgan yuqori sifatli klinik va eksperimental tadqiqotlar asosida amalga oshirildi. Tahlil natijalari metabolik sindrom va uning gepatik ko‘rinishi — metabolik disfunksiya bilan bog‘liq steatoz jigar kasalligi (MASLD) dunyo aholisining taxminan uchdan birini qamrab olishini ko‘rsatdi. Metabolik sindrom sharoitida I-faza fermenti CYP2E1 ning faollashuvi reaktiv kislorod turlari (ROS) hosil bo‘lishini kuchaytirib, glutation (GSH) zaxiralarining kamayishi va antioksidant himoyaning susayishi bilan kechishi aniqlandi. Yuzaga keluvchi surunkali oksidlovchi stress lipid peroksidatsiyasi, IRS-1 oqsilining serin fosforillanishi va NF-κB ga bog‘liq yallig‘lanish orqali insulin rezistentligini yanada kuchaytiruvchi qaytar patofiziologik halqani shakllantiradi. Hayot tarzini modifikatsiya qilish (tana vaznining 5–10 % ga kamayishi), Nrf2 faollashtiruvchi nutritsevtiklar, GLP-1 retseptor agonistlari hamda 2024-yilda MASH davolashda tasdiqlangan birinchi dori — rezmetirom integrativ terapiyaning istiqbolli yo‘nalishlari sifatida aniqlandi. Olingan natijalar jigar detoksifikatsiya funksiyasini metabolik sindromni boshqarishda muhim patofiziologik nishon sifatida e’tirof etish zarurligini ishonchli ilmiy asosda tasdiqlaydi.References
1. Trefts E., Gannon M., Wasserman D.H. The liver. Current Biology, 2017, 27(21), R1147–R1151. https://doi.org/10.1016/j.cub.2017.09.019
2. Almazroo O.A., Miah M.K., Venkataramanan R. Drug Metabolism in the Liver. Clinics in Liver Disease, 2017, 21(1), 1–20. https://doi.org/10.1016/j.cld.2016.08.001
3. Hodges R.E., Minich D.M. Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application. Journal of Nutrition and Metabolism, 2015, 760689. https://doi.org/10.1155/2015/760689
4. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 2018, 20(2), 12. https://doi.org/10.1007/s11906-018-0812-z
5. Ahmed M., et al. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Molecular Medicine, 2024, 30, 279. https://doi.org/10.1186/s10020-024-01019-y
6. Rinella M.E., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023, 78(6), 1966–1986. https://doi.org/10.1097/HEP.0000000000000520
7. Le M.H., et al. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 2025, 31(Suppl), S32–S50. https://doi.org/10.3350/cmh.2024.0431
8. Cederbaum A.I. Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications. Redox Biology, 2015, 4, 60–73. https://doi.org/10.1016/j.redox.2014.11.008
9. Abdelmegeed M.A., et al. Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis. Scientific Reports, 2017, 7, 39764. https://doi.org/10.1038/srep39764
10. Petersen M.C., Shulman G.I. Mechanisms of Insulin Action and Insulin Resistance. Physiological Reviews, 2018, 98(4), 2133–2223. https://doi.org/10.1152/physrev.00063.2017
11. Gong P., Cederbaum A.I. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology, 2006, 43(1), 144–153. https://doi.org/10.1002/hep.21004
12. Harrison S.A., et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine, 2024, 390(6), 497–509. https://doi.org/10.1056/NEJMoa2309000
13. Khabibullaev S., Yuldashev N., Mamazulunov N. Metabolic changes in the body as the result of long-term use of artificial sweetener — sodium cyclamate. Science and Innovation, 2023, 2(D10), 64–70.
14. Tilg H., Adolph T.E., Tréharé M. The gut–liver axis in metabolic dysfunction-associated steatotic liver disease. Nature Reviews Gastroenterology & Hepatology, 2024, 21(8), 561–575. https://doi.org/10.1038/s41575-024-00904-5
15. Мамазулунов, Н. Х., Ботиров, Э. Х., & Юсупов, М. М. (2020). Флавоноиды russowia sogdiana (BGE). fedsch. Экономика и социум, (12 (79)), 628-631.
16. Bokiyev, M., & Mamazulunov, N. (2020). Some biological active products of metallocenes. Экономика и социум, (12 (79)), 67-70.
17. Икрамова, М. М., Таджибоев, К. Т., & Мамазулунов, Н. Х. (2013). Определение активности аминотрансфераза в перфузате печени при экспериментальном токсическом гепатите. science and world, 42.
18. Юлдашев, Н., Мамазулунов, Н., & Хабибуллаев, С. Научное обозрение. Биологические науки. Научное обозрение, (2), 51-57.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Nurmuhammad Xusanboy o'g'li Mamazulunov, Qudratillo Mashrabboy o'g'li Axmadjonov, Nosirbek Abdullayevich Jumayev (Author)